Novel therapeutic options with improved efficacy and safety profiles are needed for the prophylaxis of migraine. In recent years, the inhibition of calcitonin gene-related peptide (CGRP) signaling has attracted growing interest in the pharmacological research on migraine. Erenumab is the first fully human monoclonal antibody directed against the CGRP receptor to be approved for use in migraineurs.

Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety / Lattanzi, Simona; Brigo, Francesco; Trinka, Eugen; Vernieri, Fabrizio; Corradetti, Tommaso; Dobran, Mauro; Silvestrini, Mauro. - In: DRUGS. - ISSN 0012-6667. - STAMPA. - (2019). [10.1007/s40265-019-01069-1]

Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety

Lattanzi, Simona
;
Corradetti, Tommaso
Investigation
;
Dobran, Mauro
Investigation
;
Silvestrini, Mauro
Supervision
2019-01-01

Abstract

Novel therapeutic options with improved efficacy and safety profiles are needed for the prophylaxis of migraine. In recent years, the inhibition of calcitonin gene-related peptide (CGRP) signaling has attracted growing interest in the pharmacological research on migraine. Erenumab is the first fully human monoclonal antibody directed against the CGRP receptor to be approved for use in migraineurs.
2019
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/263965
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 74
  • ???jsp.display-item.citation.isi??? 65
social impact